Loading...

Monensin Solution (1,000X)

Pricing & Availability
Regulatory Status
RUO
Ave. Rating
Submit a Review
Product Citations
publications
Cat # Size Price Quantity Check Availability Save
420701 1 mL 54 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Monensin is a protein transport inhibitor commonly used to enhance intracellular cytokine staining signals by blocking transport processes during cell activation. Especially useful for the intracellular staining of cytokines, monensin leads to the accumulation of most cytokines at the Golgi Complex/Endoplasmic Reticulum (see Jung, et al., 1993). Optimal conditions for use are cell type and time-dependent. Typically, protein transport inhibitors are included during in vitro cell activation cultures for 4-24 hours prior to harvest (see references below for additional information). Monensin Solution is supplied as a 1,000X solution, which should be diluted to 1X in cell culture medium.

Product Details
Technical Data Sheet (pdf)

Product Details

Formulation
Monensin Solution is supplied as a 1000X working solution in 70% Ethanol. Dilute to 1X in cell culture medium.
Concentration
2.0 mM
Storage & Handling
Store the solution between 2°C and 8°C. Monensin is known to be toxic; avoid direct body contact. Ethanol is flammable; keep away from sources of fire.
Application

ICFC - Quality tested
Recommended Usage

Dilute the 1000X solution to 1X in the tissue culture medium. It is recommended that cells are cultured with monensin for ≤ 24 hours, as this can become toxic for cell viability.

Application References

(PubMed link indicates BioLegend citation)
  1. Smeltz RB. 2007. J. Immunol. 178:4786.
  2. Fuse S, et al. 2007. J. Immunol. 178:5227.
  3. Durkin ET,et al. 2008. Blood 10:1182.PubMed
  4. Durkin ET, et al. 2008. Blood 112:5245. PubMed
  5. Liu XS, et al. 2009. J. Immunol. 183:51. PubMed
  6. Mattarollo SR, et al. 2010. J. Immunol. 184:1242. PubMed
  7. Yang M, et al. 2010. J. Immuonl. 184:3321. PubMed
  8. Mattarollo SR, et al. 2010. J. Immunol. 184:5663. PubMed
  9. Wood MW, et al. 2011. Infect Immun. 79:708. PubMed
  10. Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed
  11. Fiorenza S, et al. 2012. J. Immunol. 189:5622. PubMed
  12. Asgari E, et al. 2013. Blood. 122:3473. PubMed
  13. Li D, et al. 2013. Clin Immunol. 149:411. PubMed
  14. Bunse CE, et al. 2013. PLoS One. 8:77925. PubMed
Product Citations
  1. Pal R, et al. 2020. Curr Protoc Cytom. 92:e69. PubMed
  2. Bhatt RS, et al. 2021. Cancer Immunol Res. 9:156. PubMed
  3. Yu L, et al. 2022. FEBS J. 289:3241. PubMed
  4. Zhang X, et al. 2022. Nat Commun. 13:7582. PubMed
  5. Giannou AD, et al. 2023. Immunity. 56:125. PubMed
  6. Martinelli M, et al. 2023. iScience. 26:105860. PubMed
  7. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  8. Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed
  9. Pymm P, et al. 2022. Cell Rep. 38:110449. PubMed
  10. Giles JR, et al. 2022. Immunity. 55:557. PubMed
  11. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  12. Li D, et al. 2013. Clin Immunol. 149:411. PubMed
  13. Mattarollo S, et al. 2010. J Immunol. 184:1242. PubMed
  14. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  15. Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed
  16. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
  17. Kozlovski S, et al. 2023. Front Immunol. 13:1041552. PubMed
  18. Zhou Y, et al. 2023. Front Immunol. 14:1129705. PubMed
  19. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  20. Comeau K, et al. 2023. Bio Protoc. 13:e4679. PubMed
  21. Frankish J, et al. 2023. Front Immunol. 14:1160116. PubMed
  22. Patskovsky Y, et al. 2023. Nat Commun. 14:3763. PubMed
  23. Pan YG, et al. 2022. Methods Mol Biol. 2574:31. PubMed
  24. Aguilar-Pineda JA, et al. 2021. iScience. 24:102993. PubMed
  25. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  26. Andrew Mansour, Laurentiu Pop, Ellen Vitetta 2016. PLoS One. 11:e0167618. PubMed
  27. Asgari E, et al. 2013. Blood. 122:3473. PubMed
  28. Munk R, et al. 2011. PLoS One. 6:e18553. PubMed
  29. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  30. Durkin E, et al. 2008. Blood. 112:5245. PubMed
  31. Cook CP, et al. 2022. Cell Rep Med. 3:100715. PubMed
  32. Tian M, et al. 2022. J Clin Invest. 132:. PubMed
  33. Kimura I, et al. 2022. Cell Rep. 38:110218. PubMed
  34. Gao F, et al. 2021. Front Cell Infect Microbiol. 10:593805. PubMed
  35. Yang M, et al. 2010. J Immunol. 184:3321. PubMed
  36. Izumi K, et al. 2021. Immunohorizons. 5:687. PubMed
  37. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  38. Datta A, et al. 2022. J Fungi (Basel). 8:. PubMed
  39. Martens A, et al. 2020. Nat Immunol. 21:381. PubMed
  40. Theeb W, et al. 2017. Infect Immun . 10.1128/IAI.00475-16. PubMed
  41. Al-Attar A, et al. 2016. Data Brief. 8: 536-44. PubMed
  42. Joosten S, et al. 2016. PLoS Pathog. 12: 1005687. PubMed
  43. Fiorenza S, et al. 2012. J Immunol. 189:5622. PubMed
  44. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  45. Geisness AC, et al. 2021. Haematologica. Online ahead of print. PubMed
  46. Douthwaite J, et al. 2017. J Immunol. 198(1):528-537. PubMed
  47. Meyer C, Key P 2017. Imm Inflam Dis. 10.1002/iid3.156. PubMed
  48. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  49. Steinbuck MP, et al. 2021. Sci Adv. 7: . PubMed
  50. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  51. Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed
  52. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  53. Ries M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006506. PubMed
  54. Shenoy AT, et al. 2021. Nat Commun. 12:5834. PubMed
  55. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  56. Elliott PR, et al. 2021. Cell Rep. 37:109777. PubMed
  57. Bunting MD, et al. 2022. Sci Adv. 8:eabk3327. PubMed
  58. Uddin MN, et al. 2022. Brain Behav Immun Health. 26:100563. PubMed
  59. Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed
  60. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  61. Mittal P, et al. 2020. Cancers (Basel). :12. PubMed
  62. Gross C, et al. 2016. Neurol Neuroimmunol Neuroinflamm. 3: e289. PubMed
  63. Orlov M, et al. 2017. PLoS One.. 10.1371/journal.pone.018296. PubMed
  64. Vacaflores A, et al. 2016. PLoS One. 11: 0157175. PubMed
  65. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  66. Huang RS, et al. 2021. Curr Protoc. 1:e246. PubMed
  67. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  68. Nice T, et al. 2016. PLoS One. 12: 1005684. PubMed
  69. Krishnan A, et al. 2020. Am J Pathol. 190:1284. PubMed
  70. Ngwenyama N, et al. 2019. JCI Insight. 4:e125527. PubMed
  71. Chen YF, et al. 2019. J Biomed Sci. 26:85. PubMed
  72. de Picciotto S, et al. 2022. Nat Commun. 13:3866. PubMed
  73. Shafer S, et al. 2021. J Allergy Clin Immunol. 148:256. PubMed
  74. Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed
  75. Loeuillard E, et al. 2020. J Clin Invest. 130:5380. PubMed
  76. Liu X, et al. 2009. J Immunol. 183:51:00. PubMed
  77. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  78. Ren Y, et al. 2015. Biochim Biophys Acta. Available online 14 August 2015. PubMed
  79. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  80. Wood M, et al. 2011. Infect Immun. 79:708. PubMed
  81. Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed
  82. FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed
  83. Dimeloe S, et al. 2016. J Immunol. 196: 106 - 114. PubMed
  84. Bunse C, et al. 2013. PLoS One. 8:77925. PubMed
  85. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  86. Landi A, et al. 2017. Vaccine.. 10.1016/j.vaccine.2017.10.072. PubMed
  87. Liu X, et al. 2020. Ther Adv Med Oncol. 12:1758835920910347. PubMed
  88. Seenappa LM, et al. 2022. NPJ Vaccines. 7:128. PubMed
  89. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  90. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  91. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  92. Krishna B, et al. 2016. Sci Rep. 6: 24674. PubMed
  93. Schridde A, et al. 2017. Mucosal Immunol. 10.1038/mi.2016.142. PubMed
  94. Ruland C, et al. 2017. Brain Behav Immun. 10.1016/j.bbi.2017.06.010. PubMed
  95. Mattarollo S, et al. 2010. J Immunol. 184:5663. PubMed
  96. Kumar S, et al. 2021. JCI Insight. 6:e145228. PubMed
  97. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  98. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  99. Marvin S, et al. 2017. J Virol. 10.1128/JVI.01417-16. PubMed

Antigen Details

Antigen References

1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 Detection of Intracellular Cytokines by Flow Cytometry (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD).
2. Sander B, et al. 1991. Immunol. Rev. 119:65.
3. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
4. Prussin C, et al. 1995. J. Immunol. Meth. 188:117.
5. Jung T, et al. 1993. J. Immunol. Meth. 159:197.

Gene ID
NA

Related FAQs

How do I choose monensin or Brefeldin A solution?

Generally, Brefeldin A is more toxic for longer term incubations, so for shorter stimulations (6 hrs or less) use Brefeldin A.  For longer stimulations use monensin.  We recommend optimization for each cell type and protocol.

Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account